Fig. 2From: Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trialSummary of HBV DNA SVR (a), HBeAg conversion rate (b), and change in serum HBsAg levels after treatments (c) by groups. The change in HBsAg levels after therapy was calculated as the difference between baseline HBsAg level and the HBsAg level at a specific time point. HBV DNA SVR was represented as percentage of rate and the change in HBsAg levels was represented as mean with standard deviation (SD).* P < 0.001, indicates a significant differenceBack to article page